TRCT
RNTX

Tower Research Capital (TRC)’s Rein Therapeutics RNTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,391
Closed -$4.41K – 5761
2026
Q1 		$4.41K Buy
3,391
+1,434
+73% +$1.78K ﹤0.01% 4201
2025
Q4 		$2.27K Sell
1,957
-3,072
-61% -$4.23K ﹤0.01% 4564
2025
Q3 		$5.76K Buy
5,029
+2,098
+72% +$2.66K ﹤0.01% 4205
2025
Q2 		$4.1K Sell
2,931
-526
-15% -$947 ﹤0.01% 4380
2025
Q1 		$6.12K Buy
3,457
+877
+34% +$1.84K ﹤0.01% 4066
2024
Q4 		$5.93K Buy
2,580
+2,337
+962% +$7.08K ﹤0.01% 4224
2024
Q3 		$860 Sell
243
-3,621
-94% -$9.68K ﹤0.01% 5251
2024
Q2 		$10.7K Buy
3,864
+1,844
+91% +$7.58K ﹤0.01% 4127
2024
Q1 		$13.4K Sell
2,020
-206
-9% -$986 ﹤0.01% 3398
2023
Q4 		$6.79K Sell
2,226
-2,283
-51% -$4.45K ﹤0.01% 4697
2023
Q3 		$6.85K Buy
4,509
+767
+20% +$1.3K ﹤0.01% 4548
2023
Q2 		$6.7K Buy
3,742
+429
+13% +$661 ﹤0.01% 4672
2023
Q1 		$4K Buy
3,313
+909
+38% +$1.95K ﹤0.01% 5122
2022
Q4 		$5K Buy
+2,404
New +$8.08K ﹤0.01% 4931
2022
Q3 		– Sell
-1,685
Closed -$9K – 6575
2022
Q2 		$9K Buy
1,685
+1,188
+239% +$10.9K ﹤0.01% 4600
2022
Q1 		$5K Buy
497
+444
+838% +$4.02K ﹤0.01% 5127
2021
Q4 		$1K Buy
+53
New +$820 ﹤0.01% 5904
2021
Q3 		– Sell
-136
Closed -$3K – 6260
2021
Q2 		$3K Buy
+136
New +$3.39K ﹤0.01% 4970
2020
Q4 		– Sell
-203
Closed -$5K – 5461
2020
Q3 		$5K Buy
+203
New +$4.78K ﹤0.01% 4383
2019
Q1 		– Sell
-62
Closed -$1K – 4362
2018
Q4 		$1K Buy
62
+52
+520% +$2.09K ﹤0.01% 3686
2018
Q3 		$1K Buy
10
+7
+233% +$471 ﹤0.01% 3640
2018
Q2 		$0 Sell
3
-23
-88% -$2.6K ﹤0.01% 4133
2018
Q1 		$4K Sell
26
-14
-35% -$2.5K ﹤0.01% 2814
2017
Q4 		$8K Buy
+40
New +$9.59K ﹤0.01% 2692

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Tower Research Capital (TRC)'s RNTX Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Rein Therapeutics (RNTX) in Q2 2026, closing a stake of 3,391 shares — an estimated $4.41K sold.

Tower Research Capital (TRC) first reported a position in RNTX in Q4 2017 and held it in 24 quarters. The position peaked at $13.4K in Q1 2024. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining Rein Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 3,391 Rein Therapeutics shares in Q2 2026, an estimated $4.41K.
  • Tower Research Capital (TRC) first reported a position in Rein Therapeutics in Q4 2017 and held it in 24 quarters.
  • Tower Research Capital (TRC)'s Rein Therapeutics position peaked at $13.4K in Q1 2024.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.